192 related articles for article (PubMed ID: 14997189)
21. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
[TBL] [Abstract][Full Text] [Related]
22. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.
Morschhauser F; Fitoussi O; Haioun C; Thieblemont C; Quach H; Delarue R; Glaisner S; Gabarre J; Bosly A; Lister J; Li J; Coiffier B
Eur J Cancer; 2013 Sep; 49(13):2869-76. PubMed ID: 23731832
[TBL] [Abstract][Full Text] [Related]
23. Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report.
Berg SL; Cairo MS; Russell H; Ayello J; Ingle AM; Lau H; Chen N; Adamson PC; Blaney SM
J Clin Oncol; 2011 Jan; 29(3):316-23. PubMed ID: 21149673
[TBL] [Abstract][Full Text] [Related]
24. Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer.
Said R; Kakadiaris E; Piha-Paul S; Fu S; Falchook G; Janku F; Wheler JJ; Zinner R; Hong DS; Kurzrock R; Tsimberidou AM
Cancer Chemother Pharmacol; 2016 May; 77(5):1097-102. PubMed ID: 27085994
[TBL] [Abstract][Full Text] [Related]
25. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
Ribas A; Gonzalez R; Pavlick A; Hamid O; Gajewski TF; Daud A; Flaherty L; Logan T; Chmielowski B; Lewis K; Kee D; Boasberg P; Yin M; Chan I; Musib L; Choong N; Puzanov I; McArthur GA
Lancet Oncol; 2014 Aug; 15(9):954-65. PubMed ID: 25037139
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026.
Hutchins LF; Moon J; Clark JI; Thompson JA; Lange MK; Flaherty LE; Sondak VK
Cancer; 2007 Nov; 110(10):2269-75. PubMed ID: 17932881
[TBL] [Abstract][Full Text] [Related]
27. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
28. Intralesional granulocyte-monocyte colony-stimulating factor followed by subcutaneous interleukin-2 in metastatic melanoma: a pilot study in elderly patients.
Ridolfi L; Ridolfi R; Ascari-Raccagni A; Fabbri M; Casadei S; Gatti A; Trevisan G; Righini MG
J Eur Acad Dermatol Venereol; 2001 May; 15(3):218-23. PubMed ID: 11683284
[TBL] [Abstract][Full Text] [Related]
29. Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients.
Tang B; Yan X; Sheng X; Si L; Cui C; Kong Y; Mao L; Lian B; Bai X; Wang X; Li S; Zhou L; Yu J; Dai J; Wang K; Hu J; Dong L; Song H; Wu H; Feng H; Yao S; Chi Z; Guo J
J Hematol Oncol; 2019 Jan; 12(1):7. PubMed ID: 30642373
[TBL] [Abstract][Full Text] [Related]
30. A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma.
Grignol VP; Olencki T; Relekar K; Taylor C; Kibler A; Kefauver C; Wei L; Walker MJ; Chen HX; Kendra K; Carson WE
J Immunother; 2011; 34(6):509-15. PubMed ID: 21654521
[TBL] [Abstract][Full Text] [Related]
31. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R; Kaufman JL; Berg D; Liao E; Di Bacco A; Estevam J; Gupta N; Hui AM; Rajkumar V; Richardson PG
Lancet Oncol; 2014 Dec; 15(13):1503-1512. PubMed ID: 25456369
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma.
Chan JK; Manuel MR; Ciaravino G; Cheung MK; Husain A; Teng NN
Gynecol Oncol; 2006 Dec; 103(3):919-23. PubMed ID: 16828852
[TBL] [Abstract][Full Text] [Related]
33. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
[TBL] [Abstract][Full Text] [Related]
34. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study.
Hwu WJ; Lis E; Menell JH; Panageas KS; Lamb LA; Merrell J; Williams LJ; Krown SE; Chapman PB; Livingston PO; Wolchok JD; Houghton AN
Cancer; 2005 Jun; 103(12):2590-7. PubMed ID: 15861414
[TBL] [Abstract][Full Text] [Related]
35. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma.
Daliani DD; Papandreou CN; Thall PF; Wang X; Perez C; Oliva R; Pagliaro L; Amato R
Cancer; 2002 Aug; 95(4):758-65. PubMed ID: 12209719
[TBL] [Abstract][Full Text] [Related]
36. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
Danson S; Lorigan P; Arance A; Clamp A; Ranson M; Hodgetts J; Lomax L; Ashcroft L; Thatcher N; Middleton MR
J Clin Oncol; 2003 Jul; 21(13):2551-7. PubMed ID: 12829675
[TBL] [Abstract][Full Text] [Related]
37. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma.
Varker KA; Biber JE; Kefauver C; Jensen R; Lehman A; Young D; Wu H; Lesinski GB; Kendra K; Chen HX; Walker MJ; Carson WE
Ann Surg Oncol; 2007 Aug; 14(8):2367-76. PubMed ID: 17534686
[TBL] [Abstract][Full Text] [Related]
38. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
McMeekin DS; Sill MW; Darcy KM; Stearns-Kurosawa DJ; Webster K; Waggoner S; Benbrook D
Gynecol Oncol; 2007 Sep; 106(3):596-603. PubMed ID: 17597196
[TBL] [Abstract][Full Text] [Related]
39. Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: a randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma.
Smith II JW; Kurt RA; Baher AG; Denman S; Justice L; Doran T; Gilbert M; Alvord WG; Urba WJ
J Immunother; 2003; 26(2):130-8. PubMed ID: 12616104
[TBL] [Abstract][Full Text] [Related]
40. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.
Martin T; Baz R; Benson DM; Lendvai N; Wolf J; Munster P; Lesokhin AM; Wack C; Charpentier E; Campana F; Vij R
Blood; 2017 Jun; 129(25):3294-3303. PubMed ID: 28483761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
